Sinovac cuts full-year revenue forecast

Sinovac Biotech shares fell 10 percent Monday, a day after the vaccine manufacturer cut its full-year revenue forecast for the second time, citing continued weakness in Chinese demand for vaccines. "The vaccine market in China is experiencing a much longer than originally expected demand weakness in the market following the unfounded media reports about vaccine safety in China's Shanxi province," the company says in a release. Sinovac release | Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.